The backbone of progress - preclinical studies and innovations with zoledronic acid

Critical Reviews in Oncology/Hematology

Volumn 77, Issue SUPPL.1, 2011, Pages

  Green, Jonathan R ^a   Guenther, Andreas ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Anticancer; Bisphosphonates; Myeloma; Preclinical; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FARNESYL TRANS TRANSFERASE; GERANYLTRANSFERASE; HYDROXYUREA; IBANDRONIC ACID; IMATINIB; INTERLEUKIN 2; INTERLEUKIN 6; ISOPENTENYL DIPHOSPHATE; M PROTEIN; MEVALONIC ACID; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE ATROPHY; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG MECHANISM; GAMMA DELTA T LYMPHOCYTE; GROWTH INHIBITION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OSTEOCLAST; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PLASMACYTOMA; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLES; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS;

EID: 79951817613     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(11)70003-8     Document Type: Review

References (91)

1. Fleisch H Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42:919-944.
2. Boyle WJ, Simonet WS, Lacey DL Osteoclast differentiation and activation. Nature 2003, 423:337-342.
3. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
4. Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
5. Bondronat (ibandronate) 2mg and 6mg concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, Hertfordshire, United Kingdom: Roche; 2010.
6. Zometa (zoledronic acid) injection [package insert] 2008, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
7. Bonefos (disodium clodronate) [package insert] 2008, Bayer Schering Pharma, Oy, Turku, Finland.
8. Aredia (pamidronate disodium) injection [package insert] 2008, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
9. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.
10. Aveu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, et al. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005, 74:496-500.
11. Clezardin P Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone 2011, 48:71-79.
12. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005, 104:118-125.
13. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815.
14. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003, 18:482-492.
15. Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001, 29:441-447.
16. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697-1706.
17. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048-2056.
18. Giraudo E, Inoue M, Hanahan D An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
19. Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002, 119:475-483.
20. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126:239-246.
21. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44:908-916.
22. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004, 79:37-43.
23. Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, et al. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 2007, 79:382-391.
24. Kunzmann Y, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
25. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD 137 engagement. Blood 2010, 116:1726-1733.
26. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005, 19:664-670.
27. Martinez-Jaramillo G, Vela-Ojeda J, Flores-Guzman P, Mayani H. In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leuk Res 2010 [Epub ahead of print, July 9, 2010].
28. Monkkonen H, Kuokkanen J, Holen I, Evans A, Lefley W, Jauhiainen M, et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19:391-399.
29. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010, 46:420-429.
30. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009, 8:2821-2832.
31. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007, 6:3256-3262.
32. Segawa H, Kimura S, Kuroda J, Sato K, Yokota A, Kawata E, et al. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. Br J Haematol 2005, 130:558-560.
33. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294-5297.
34. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997, 98:665-672.
35. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli Y, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14:841-844.
36. Ural AU, Yilmaz MI, Aveu F, Pekel A, Zerman M, Nevruz O, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003, 78:443-449.
37. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010, 103:629-641.
38. Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009, 151:115-120.
39. Costa L, Harper P, Coleman RE, Lipton A Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 2011, 77(l):S31-S37.
40. Cook R Introduction: multiple myeloma. J Manag Care Pharm 2008, 14:4-6.
41. Jagannath S Pathophysiological underpinnings of multiple myeloma progression. J Manag Care Pharm 2008, 14:7-11.
42. Schwartz RN, Vozniak M Current and emerging treatments for multiple myeloma. J Manag Care Pharm 2008, 14:12-19.
43. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009, 114:3625-3628.
44. Giuliani N, Rizzoli V, Roodman GD Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996.
45. Yeh HS, Berenson JR Treatment for myeloma bone disease. Clin Cancer Res 2006, 12:6279s-6284s.
46. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FR Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16:2950-2960.
47. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sei 2007, 1117:209-257.
48. Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, et al. Bisphosphonates - mechanisms of action in multiple myeloma. Acta Oncol 2000, 39:829-835.
49. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43:154-162.
50. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
51. Thompson K, Rogers MJ, Coxon FP, Crockett JC Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69:1624-1632.
52. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
53. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, et al. Bisphosphonates target multiple sites in both eis- and trans-prenyl transferases. Proc Natl Acad Sei U S A 2007, 104:10022-10027.
54. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 2002, 21:867-873.
55. Takahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001, 25:77-83.
56. van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362.
57. Salomo M, Jurlander J, Nielsen LB, Gimsing P How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 2003, 122:202-210.
58. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997, 37:285-290.
59. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone métastases. J Clin Pharmacol 2002, 42:1228-1236.
60. Cheung WK, Brunner L, Schoenfeld S, Knight R, Seaman J, Brox A, et al. Pharmacokinetics of pamidronate disodium in cancer patients after a single intravenous infusion of 30-, 60- or 90-mg dose over 4 or 24 hours. Am J Ther 1994, 1:228-235.
61. Radl J, Croese JW, Zürcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, et al. Influence of treatment with APD- bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985, 55:1030-1040.
62. Croese JW, Vissinga CS, Boersma WJ, Radl J Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma 1991, 38:457-466.
63. Croese JW, Van den Enden-Vieveen MH, Radl J Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma 1991, 38:467-474.
64. Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, et al. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol 2000, 111:283-286.
65. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290.
66. Fowler JA, Edwards CM, Croucher PI Tumor-host cell interactions in the bone disease of myeloma. Bone 2010, 48:121-128.
67. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
68. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007, 21:1007-1034. vii-viii.
69. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007, 20:597-612.
70. Dalton WS Drug resistance and drug development in multiple myeloma. Semin Oncol 2002, 29:21-25.
71. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009, 23:1515-1527.
72. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
73. Olson K, Van Poznak C Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007, 13:223-229.
74. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009, 37:956-968.
75. Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 2007, 354:613-618.
76. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkko-nen J, et al. Zoledronic acid-induced IPP/ApppI (phosphoantigen) accumulation in human breast cancer cells correlates with Vγ9Vδ2 T cell-mediated cancer cell death in vitro and in vivo. Bone 2010, 46(Suppl):S43.
77. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197:163-168.
78. Saitoh A, Narita M, Watanabe N, Tochiki N, Satoh N, Takizawa J, et al. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 2008, 25:137-147.
79. Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, et al. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leuk Res 2006, 30:529-535.
80. Petrini I, Pacini S, Petrini M, Fazzi R, Trombi L, Galimberti S Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur J Clin Invest 2009, 39:813-818.
81. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-Macgregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
82. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
83. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
84. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010, 21:2188-2194.
85. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
86. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengrueth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010, 28(Suppl):75s. [abstract 533].
87. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(Suppl):20s. [abstract 559].
88. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
89. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
90. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(Suppl 2):170S-171S. [abstract 2048].
91. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.